DRUG INTERACTIONS AND ADVERSE DRUG REACTIONS STUDY OF HIV/AIDS PATIENTS WITH TUBERCULOSIS IN DR. HASAN SADIKIN HOSPITAL BANDUNG

• Main Author: Vania Andi, Alexandra
• Format: Theses
• Language: Indonesia
• Online Access: https://digilib.itb.ac.id/gdl/view/45965
• Institution: Institut Teknologi Bandung

Tuberculosis is a disease that often occurs in patients with HIV/AIDS. Both HIV/AIDS and tuberculosis require combination therapy with many kind of drugs. Using many kind of drugs can lead to drug interactions and unwanted drug effects or adverse drug reactions (ADRs). This study aims to determine the potential of drug interactions in HIV/AIDS patients with tuberculosis, estimation of ADRs occured, and also treatment recommendations for HIV/AIDS patients with tuberculosis. This research is a descriptive study which has done retrospectively in HIV/AIDS patients with tuberculosis who began the treatment in the Teratai clinic, Dr. Hasan Sadikin Bandung Hospital in 2013. This study obtains 48 patients that fit the inclusion criteria, namely adult patients, receiving treatment for tuberculosis in Teratai clinic, Dr. Hasan Sadikin Bandung Hospital in 2013, and has been receiving treatment for tuberculosis and antiretroviral therapy. Based on those patients, there were 109 incidences of potential drug interactions with major significance, 299 incidences of potential drug interactions with moderate significance, and 58 the incidences of potential drug interactions with minor significance. Estimated ADRs with the greatest number found in this study was 8 incidences of gastrointestinal disorders, 5 incidences of drug eruption, 5 drug-induced liver injury (DILI) incidences, and 4 peripheral neuropathy incidences. Patients receiving tuberculosis therapy category 1 was recommended to use tenofovir, lamivudine, and efavirenz as antiretroviral therapy, whereas patients receiving tuberculosis therapy category 2 was recommended to use zidovudine, lamivudine, and efavirenz as antiretroviral therapy. Based on this study, there were many potential drug interactions and estimated ADRs on HIV/AIDS patients with tuberculosis. To manage those effects, we can choose other drugs that interact minimally or provide other medications to prevent drug interactions and ADRs.